Assembly Biosciences Company Insiders

Assembly Biosciences' latest congressional trading

Assembly Biosciences Management Team Effectiveness

The company has return on total asset (ROA) of (0.3472) % which means that it has lost $0.3472 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.0178) %, meaning that it created substantial loss on money invested by shareholders. Assembly Biosciences' management efficiency ratios could be used to measure how well Assembly Biosciences manages its routine affairs as well as how well it operates its assets and liabilities. As of November 21, 2024, Return On Tangible Assets is expected to decline to -0.47. In addition to that, Return On Capital Employed is expected to decline to -0.69. At present, Assembly Biosciences' Net Tangible Assets are projected to increase significantly based on the last few years of reporting. The current year's Asset Turnover is expected to grow to 0.07, whereas Total Assets are forecasted to decline to about 130.2 M. As of November 21, 2024, Common Stock Shares Outstanding is expected to decline to about 4.3 M. In addition to that, Net Loss is expected to decline to about (88 M)

Assembly Biosciences Workforce Comparison

The company has Profit Margin (PM) of (2.12) %, which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of (1.43) %, which suggests for every $100 dollars of sales, it generated a net operating loss of $1.43.

Assembly Biosciences Insider Trading History

Assembly Biosciences Notable Stakeholders

The success or failure of an entity such as Assembly Biosciences often depends on how effective the management is. Assembly Biosciences management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Assembly management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Assembly management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.

Please note, the presentation of Assembly Biosciences' financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Assembly Biosciences' management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of Assembly Biosciences' management manipulating its earnings.

When running Assembly Biosciences' price analysis, check to measure Assembly Biosciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Assembly Biosciences is operating at the current time. Most of Assembly Biosciences' value examination focuses on studying past and present price action to predict the probability of Assembly Biosciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Assembly Biosciences' price. Additionally, you may evaluate how the addition of Assembly Biosciences to your portfolios can decrease your overall portfolio volatility.